Vienna, June 12, 2015 – Promising results from an early phase trial combining the anti-bcl-2 drug Venetoclax with Rituximab to eliminate CLL are presented by Dr Andrew Roberts.

Vienna, June 12, 2015 – On behalf of the EUTOS network, Dr Hoffmann will present data of a web-based registry of newly diagnosed CML patients.

Vienna, June 12, 2015 – On behalf of the ELOQUENT-2 investigators, Dr Dimopoulos will present the positive results on Elotuzumab with Lenalidomide from a phase III study in patients with multiple myeloma.

Vienna, June 12, 2015 –Dr Guryanova will present a new mechanism for chemoresistance in AML based on acquired DNA mutations.

Vienna, June 12, 2015 –Dr Marneth will discuss the findings of eight new genetic variants in GFI1B that have been discovered in patients with bleeding and platelet disorders and consequences for new therapeutic targets.

Vienna, June 12, 2015 –Dr Mesa will present new data from the phase 3 PERSIST-1 study on improving disease symptoms and quality of life for patients with myelofibrosis.

Vienna, June 12, 2015 – Dr Ehninger will present the results of a phase II randomized study on the safety and efficacy of Sorafenib.

At the Congress of the European Hematology Association (EHA) – attracting 10,000 hematologists from Europe and beyond - the president of EHA, Prof. Christine Chomienne, called upon the European Union to deliver funding for Research into Blood Disorders:

“The hematologists in Europe have done a great work. Now it’s the EU’s turn to deliver.”